Sanctuary Advisors LLC Sells 4,650 Shares of Illumina, Inc. $ILMN

Sanctuary Advisors LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 18.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,592 shares of the life sciences company’s stock after selling 4,650 shares during the quarter. Sanctuary Advisors LLC’s holdings in Illumina were worth $2,538,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ILMN. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Illumina by 72.0% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 5,735 shares of the life sciences company’s stock worth $707,000 after acquiring an additional 2,401 shares during the last quarter. State of Michigan Retirement System raised its position in Illumina by 1.9% in the 1st quarter. State of Michigan Retirement System now owns 36,800 shares of the life sciences company’s stock worth $4,536,000 after purchasing an additional 700 shares during the period. Principal Financial Group Inc. raised its position in Illumina by 3.8% in the 1st quarter. Principal Financial Group Inc. now owns 341,244 shares of the life sciences company’s stock worth $42,062,000 after purchasing an additional 12,624 shares during the period. 180 Wealth Advisors LLC lifted its stake in Illumina by 0.4% in the first quarter. 180 Wealth Advisors LLC now owns 34,617 shares of the life sciences company’s stock worth $4,267,000 after purchasing an additional 133 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its stake in Illumina by 18.7% in the first quarter. Citizens Financial Group Inc. RI now owns 3,055 shares of the life sciences company’s stock worth $377,000 after purchasing an additional 481 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $192.53 on Wednesday. The firm’s 50 day simple moving average is $168.22 and its 200-day simple moving average is $144.20. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a one year low of $88.00 and a one year high of $196.66. The firm has a market cap of $29.13 billion, a PE ratio of 35.01, a price-to-earnings-growth ratio of 2.73 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business earned $0.97 earnings per share. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ILMN. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Canaccord Genuity Group raised their price target on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Guggenheim boosted their price objective on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday, June 29th. Barclays upped their price objective on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. Finally, Citigroup increased their target price on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Nine investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $156.88.

Insider Transactions at Illumina

In other news, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the sale, the insider owned 20,953 shares of the company’s stock, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last 90 days. 2.90% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.